Impact of kinins in the treatment of cardiovascular diseases

Pharmacology and Therapeutics

Volumn 135, Issue 1, 2012, Pages 94-111

  Regoli, Domenico ^a   Plante, Gerard E ^b   Gobeil Jr , Fernand ^b,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Antihypertensive drugs; Bradykinin; Cardiovascular diseases; Diabetes

Indexed keywords

ALISKIREN; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KININ; LOSARTAN; NITRIC OXIDE; PROSTACYCLIN; RENIN; TRV 120027; TRV120027; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; JUXTAGLOMERULAR CELL; KALLIKREIN KININ SYSTEM; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATATION;

EID: 84861341974     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.04.002     Document Type: Review

References (288)

1. P.M. Abadir, A. Periasamy, R.M. Carey, and H.M. Siragy Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization Hypertension 48 2006 316 322 (Pubitemid 44309829)
2. S. AbdAlla, E. Zaki, H. Lother, and U. Quitterer Involvement of the amino terminus of the B(2) receptor in agonist-induced receptor dimerization J Biol Chem 274 1999 26079 26084
3. S. AbdAlla, A. Abdel-Baset, H. Lother, A. el Massiery, and U. Quitterer Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension J Mol Neurosci 26 2005 185 192 (Pubitemid 41389411)
4. L.Y. Agodoa, L. Appel, G.L. Bakris, G. Beck, J. Bourgoignie, and J.P. Briggs Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial JAMA 285 2001 2719 2728 (Pubitemid 32525368)
5. K. Akiyoshi, T. Akimitsu, M. Hara, T. Saikawa, and H. Yoshimatsu AT1 receptor blockade prevents microvascular dysfunction induced by ischemia/reperfusion injury J Atheroscler Thromb 13 2006 231 239
6. M. Al-Mallah, O. Khawaja, M. Sinno, O. Alzohaili, and A.B. Samra Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis Cardiol J 17 2010 448 456
7. F. Alhenc-Gelas, N. Bouby, C. Richer, L. Potier, R. Roussel, and M. Marre Kinins as therapeutic agents in cardiovascular and renal diseases Curr Pharm Des 17 2011 2654 2662
8. S.N. Allogho, F. Gobeil, L.H. Pheng, X.K. Nguyen-Le, W. Neugebauer, and D. Regoli Kinin B1 and B2 receptors in the mouse Can J Physiol Pharmacol 73 1995 1759 1764
9. M. Amblard, I. Daffix, P. Bedos, G. Berge, D. Pruneau, and J.L. Paquet Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety J Med Chem 42 1999 4185 4192 (Pubitemid 29483035)
10. S. Anderson, H.G. Rennke, and B.M. Brenner Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat J Clin Invest 77 1986 1993 2000 (Pubitemid 16062656)
11. M. Asano, C. Hatori, H. Sawai, S. Johki, N. Inamura, and H. Kayakiri Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997 Br J Pharmacol 124 1998 441 446 (Pubitemid 28254498)
12. R.A. Augustyniak, M. Maliszewska-Scislo, H. Chen, J. Fallucca, and N.F. Rossi Acute angiotensin-converting enzyme inhibition evokes bradykinin-induced sympathetic activation in diabetic rats Am J Physiol Regul Integr Comp Physiol 293 2007 R2260 2266
13. M. Azizi, and J. Menard Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists Circulation 109 2004 2492 2499 (Pubitemid 38720545)
14. C.M. Baker-Smith, D.K. Benjamin Jr., R.M. Califf, M.D. Murphy, J.S. Li, and P.B. Smith Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials Clin Pharmacol Ther 87 2010 668 671
15. L. Barki-Harrington, A.L. Bookout, G. Wang, M.E. Lamb, L.M. Leeb-Lundberg, and Y. Daaka Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells Biochem J 371 2003 581 587 (Pubitemid 36547643)
16. J.L. Bascands, J.P. Schanstra, R. Couture, and J.P. Girolami Bradykinin receptors: towards new pathophysiological roles Med Sci (Paris) 19 2003 1093 1100 (Pubitemid 37432473)
17. E.J. Battegay, L.S. de Miguel, M. Petrimpol, and R. Humar Effects of anti-hypertensive drugs on vessel rarefaction Curr Opin Pharmacol 7 2007 151 157 (Pubitemid 46404741)
18. S. Bélanger, V. Bovenzi, J. Côté, W. Neugebauer, M. Amblard, and J. Martinez Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor Peptides 30 2009 777 787
19. I.F. Benter, M.H. Yousif, C. Cojocel, M. Al-Maghrebi, and D.I. Diz Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction Am J Physiol Heart Circ Physiol 292 2007 H666 672
20. I.F. Benter, M.H. Yousif, F.M. Al-Saleh, R. Raghupathy, M.C. Chappell, and D.I. Diz Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester J Cardiovasc Pharmacol 57 2011 559 567
21. T. Berg, and O. Koteng Signalling pathways in bradykinin- and nitric oxide-induced hypotension in the normotensive rat; role of K+-channels Br J Pharmacol 121 1997 1113 1120 (Pubitemid 27303579)
22. K.D. Bhoola, C.D. Figueroa, and K. Worthy Bioregulation of kinins: kallikreins, kininogens, and kininases Pharmacol Rev 44 1992 1 80
23. S. Bockmann, and I. Paegelow Kinins and kinin receptors: importance for the activation of leukocytes J Leukoc Biol 68 2000 587 592
24. C. Bolego, C. Buccellati, A. Prada, R.M. Gaion, G. Folco, and A. Sala Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone FASEB J 23 2009 605 612
25. C.V. Borlongan, and D.F. Emerich Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport Brain Res Bull 60 2003 297 306 (Pubitemid 36561550)
26. S. Bosnyak, E.S. Jones, A. Christopoulos, M.I. Aguilar, W.G. Thomas, and R.E. Widdop Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors Clin Sci (Lond) 121 2011 297 303
27. V. Bovenzi, M. Savard, J. Morin, C.M. Cuerrier, M. Grandbois, and F. Gobeil Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli J Cell Physiol 222 2010 168 176
28. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, and H.H. Parving Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
29. K.B. Brosnihan, P. Li, and C.M. Ferrario Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide Hypertension 27 1996 523 528 (Pubitemid 26086221)
30. N.J. Brown, and D.E. Vaughan Angiotensin-converting enzyme inhibitors Circulation 97 1998 1411 1420 (Pubitemid 28182680)
31. F. Brunner, and W.R. Kukovetz Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion Circulation 94 1996 1752 1761 (Pubitemid 26320285)
32. J.L. Bueb, M. Mousli, Y. Landry, and D. Regoli Structure-activity studies of bradykinin analogues on rat mast cell histamine release Peptides 14 1993 685 689 (Pubitemid 23221198)
33. D.J. Campbell The kallikrein-kinin system in humans Clin Exp Pharmacol Physiol 28 2001 1060 1065 (Pubitemid 34053524)
34. D.J. Campbell, A. Kladis, and A.M. Duncan Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides Hypertension 23 1994 439 449 (Pubitemid 24102039)
35. D.J. Campbell, H. Krum, and M.D. Esler Losartan increases bradykinin levels in hypertensive humans Circulation 111 2005 315 320 (Pubitemid 40165338)
36. D.J. Campbell, Y. Zhang, D.J. Kelly, R.E. Gilbert, D.J. McCarthy, and W. Shi Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart Clin Exp Pharmacol Physiol 38 2011 623 631
37. N.R. Campbell, F.A. McAlister, R. Brant, M. Levine, D. Drouin, and R. Feldman Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program J Hypertens 21 2003 1591 1597 (Pubitemid 36994139)
38. W.B. Campbell, and I. Fleming Epoxyeicosatrienoic acids and endothelium-dependent responses Pflugers Arch 459 2010 881 895
39. R.C. Cardoso, B. Lobao-Soares, M.M. Bianchin, C.G. Carlotti Jr., R. Walz, and M. Alvarez-Silva Enhancement of blood-tumor barrier permeability by Sar-[D-Phe8]des-Arg9BK, a metabolically resistant bradykinin B1 agonist, in a rat C6 glioma model BMC Neurosci 5 2004 38
40. R.M. Carey, and S.H. Padia Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure Trends Endocrinol Metab 19 2008 84 87 (Pubitemid 351442917)
41. O.A. Carretero, and A.G. Scicli Possible role of kinins in circulatory homeostasis. State of the art review Hypertension 3 1981 I4 12 (Pubitemid 11013793)
42. O.A. Carretero, and A.G. Scicli Kinin paracrine hormone H. Fritz, I. Schmidt, G. Dietze, Conference 1989 Limbach-Verlag Braunschweig 63 78 NameConference, Location
43. J. Chao, and L. Chao Kallikrein-kinin in stroke, cardiovascular and renal disease Exp Physiol 90 2005 291 298 (Pubitemid 40685841)
44. J. Chao, B. Shen, L. Gao, C.F. Xia, G. Bledsoe, and L. Chao Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing Biol Chem 391 2010 345 355
45. J. Chao, H.J. Li, Y.Y. Yao, B. Shen, L. Gao, and G. Bledsoe Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity Hypertension 49 2007 490 497
46. M.C. Chappell, S.N. Iyer, D.I. Diz, and C.M. Ferrario Antihypertensive effects of angiotensin-(1-7) Braz J Med Biol Res 31 1998 1205 1212 (Pubitemid 28485112)
47. Z. Chen, P.A. Deddish, R.D. Minshall, R.P. Becker, E.G. Erdos, and F. Tan Human ACE and bradykinin B2 receptors form a complex at the plasma membrane FASEB J 20 2006 2261 2270 (Pubitemid 44953856)
48. M.E. Cooper Pathogenesis, prevention, and treatment of diabetic nephropathy Lancet 352 1998 213 219 (Pubitemid 28327814)
49. M.E. Cooper Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy Diabetologia 44 2001 1957 1972 (Pubitemid 33124041)
50. M.E. Cooper ACE and Diabetes P. D'Orléans-Juste, G.E. Plante, ACE inhibitors 2001 Birkhäuser Basel 177 184
51. J. Côté, M. Savard, V. Bovenzi, S. Bélanger, J. Morin, and W. Neugebauer Novel kinin B1 receptor agonists with improved pharmacological profiles Peptides 30 2009 788 795
52. R. Couture, and J.P. Girolami Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus Eur J Pharmacol 500 2004 467 485 (Pubitemid 39304028)
53. R. Couture, M. Harrisson, R.M. Vianna, and F. Cloutier Kinin receptors in pain and inflammation Eur J Pharmacol 429 2001 161 176 (Pubitemid 33043994)
54. P. Cravedi, P. Ruggenenti, and G. Remuzzi Which antihypertensive drugs are the most nephroprotective and why? Expert Opin Pharmacother 11 2010 2651 2663
55. N.L. Cruden, and D.E. Newby Clots, kinins and coronaries Atherosclerosis 183 2005 189 198 (Pubitemid 41579268)
56. N.L. Cruden, N.N. Lang, T.J. Macgillivray, N.G. Uren, K.A. Fox, and D.E. Newby Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb Heart Vessels 27 2011 179 185
57. C. Csajka, T. Buclin, H.R. Brunner, and J. Biollaz Pharmacokinetic- pharmacodynamic profile of angiotensin II receptor antagonists Clin Pharmacokinet 32 1997 1 29 (Pubitemid 27037846)
58. F. Cuculi, and P. Erne Combined neutral endopeptidase inhibitors Expert Opin Investig Drugs 20 2011 457 463
59. P. D'Orleans-Juste, G. de Nucci, and J.R. Vane Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells Br J Pharmacol 96 1989 920 926 (Pubitemid 19100050)
60. G.R. Dagenais, J. Pogue, K. Fox, M.L. Simoons, and S. Yusuf Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials Lancet 368 2006 581 588 (Pubitemid 44209181)
61. B. Dahlof, K. Pennert, and L. Hansson Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies Am J Hypertens 5 1992 95 110
62. M. de Gasparo, K.J. Catt, T. Inagami, J.W. Wright, and T. Unger International union of pharmacology. XXIII. The angiotensin II receptors Pharmacol Rev 52 2000 415 472
63. A. Dendorfer, M. Wagemann, S. Reissmann, and P. Dominiak Structural requirements for B2-agonists with improved degradation stability Immunopharmacology 45 1999 199 205
64. A. Dendorfer, S. Reibetamann, S. Wolfrum, W. Raasch, and P. Dominiak Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation Hypertension 38 2001 142 146 (Pubitemid 34224786)
65. A. Dendorfer, S. Wolfrum, U. Schafer, J.M. Stewart, N. Inamura, and P. Dominiak Potentiation of the vascular response to kinins by inhibition of myocardial kininases Hypertension 35 2000 32 37 (Pubitemid 30054233)
66. A. Deshmukh, G. Kumar, N. Kumar, R. Nanchal, F. Gobal, and A. Sakhuja Effect of Joint National Committee VII Report on Hospitalizations for Hypertensive Emergencies in the United States Am J Cardiol 108 2011 1277 1282
67. S.M. DeWire, and J.D. Violin Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology Circ Res 109 2011 205 216
68. K. Dickstein, and J. Kjekshus Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet 360 2002 752 760 (Pubitemid 35247704)
69. G. Dietze New aspects of the blood flow-augmenting and insulin-like activity of muscle exercise: possible involvement of the kallikrein-kinin- prostaglandin system (author's transl) Klin Wochenschr 60 1982 429 444 (Pubitemid 12103433)
70. G. Drapeau, N.E. Rhaleb, S. Dion, D. Jukic, and D. Regoli [Phe8 psi(CH2-NH)Arg9]bradykinin, a B2 receptor selective agonist which is not broken down by either kininase I or kininase II Eur J Pharmacol 155 1988 193 195
71. A. Dray, and M. Perkins Bradykinin and inflammatory pain Trends Neurosci 16 1993 99 104 (Pubitemid 23048436)
72. J. Duchene, J.P. Schanstra, C. Pecher, A. Pizard, C. Susini, and J.P. Esteve A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation J Biol Chem 277 2002 40375 40383 (Pubitemid 35215611)
73. J. Duchene, S.D. Chauhan, F. Lopez, C. Pecher, J.P. Esteve, and J.P. Girolami Direct protein-protein interaction between PLCgamma1 and the bradykinin B2 receptor-importance of growth conditions Biochem Biophys Res Commun 326 2005 894 900 (Pubitemid 39656003)
74. A. Duka, I. Duka, G. Gao, S. Shenouda, I. Gavras, and H. Gavras Role of bradykinin B1 and B2 receptors in normal blood pressure regulation Am J Physiol Endocrinol Metab 291 2006 E268 274
75. A. Duka, E. Kintsurashvili, I. Duka, D. Ona, T.A. Hopkins, and M. Bader Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors Hypertension 51 2008 1352 1357 (Pubitemid 351555949)
76. R. Dusing, G. Kayser, S. Wagner, H. Scherf, K. Glanzer, and H.G. Predel Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme Am J Cardiol 59 1987 50D 54D (Pubitemid 17071265)
77. V.J. Dzau, W.S. Colucci, G.H. Williams, G. Curfman, L. Meggs, and N.K. Hollenberg Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure N Engl J Med 302 1980 1373 1379
78. D.F. Emerich, R.L. Dean, C. Osborn, and R.T. Bartus The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation Clin Pharmacokinet 40 2001 105 123 (Pubitemid 32242793)
79. E.G. Erdos Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture Hypertension 16 1990 363 370 (Pubitemid 20338530)
80. E.G. Erdos, and B.M. Marcic Kinins, receptors, kininases and inhibitors-where did they lead us? Biol Chem 382 2001 43 47
81. E.G. Erdos, P.A. Deddish, and B.M. Marcic Potentiation of bradykinin actions by ACE inhibitors Trends Endocrinol Metab 10 1999 223 229 (Pubitemid 30002773)
82. E.G. Erdos, F. Tan, and R.A. Skidgel Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function Hypertension 55 2010 214 220
83. S.G. Farmer The kallikrein-kinin System in Asthma an Acute Respiratory Distress Syndrome S.G. Farmer, The Kinin system 1997 Academic Press San Diego 249 264
84. M. Feletou, and P.M. Vanhoutte EDHF: an update Clin Sci (Lond) 117 2009 139 155
85. J. Feng, N. Yamaguchi, S. Foucart, R. Chahine, D. Lamontagne, and R. Nadeau Transient ischemia inhibits nonexocytotic release of norepinephrine following sustained ischemia in rat heart: is bradykinin involved? Can J Physiol Pharmacol 75 1997 665 670 (Pubitemid 27458654)
86. R. Ferrari, G. Guardigli, and C. Ceconi Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium Cardiovasc Drugs Ther 24 2010 331 339
87. C.M. Ferrario, A.J. Trask, and J.A. Jessup Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function Am J Physiol Heart Circ Physiol 289 2005 H2281 2290
88. A.J. Ferreira, B.A. Jacoby, C.A. Araujo, F.A. Macedo, G.A. Silva, and A.P. Almeida The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction Am J Physiol Heart Circ Physiol 292 2007 H1113 1119
89. S.H. Ferreira, and J.R. Vane The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat Br J Pharmacol Chemother 30 1967 417 424
90. S.H. Ferreira, D.C. Bartelt, and L.J. Greene Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom Biochemistry 9 1970 2583 2593
91. N.D. Fisher, A.H. Jan Danser, J. Nussberger, W.P. Dole, and N.K. Hollenberg Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans Circulation 117 2008 3199 3205
92. J.P. Fortin, F. Gobeil Jr., A. Adam, D. Regoli, and F. Marceau Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor? Am J Physiol Heart Circ Physiol 285 2003 H277 282
93. D. Fulton, J.C. McGiff, and J. Quilley Role of K+ channels in the vasodilator response to bradykinin in the rat heart Br J Pharmacol 113 1994 954 958 (Pubitemid 24326839)
94. J.T. Gafford, R.A. Skidgel, E.G. Erdos, and L.B. Hersh Human kidney enkephalinase, a neutral metalloendopeptidase that cleaves active peptides Biochemistry 22 1983 3265 3271 (Pubitemid 13061677)
95. H. Gavras The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases N Engl J Med 319 1988 1541 1543
96. I. Gavras, and H. Gavras The role of ACE inhibition in heart failure P. D'Orléans-Juste, G.E. Plante, ACE inhibitors 2001 Birkhäuser Basel 77 79
97. J. Genest, R. McPherson, J. Frohlich, T. Anderson, N. Campbell, and A. Carpentier 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
98. J.P. Gies, Y. Landry, and M. Mousli Receptor-independent activation of mast cells by bradykinin and related peptides Trends Neurosci 16 1993 498 499 (Pubitemid 23341956)
99. B.D. Given, T. Taylor, N.K. Hollenberg, and G.H. Williams Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects J Cardiovasc Pharmacol 6 1984 436 441 (Pubitemid 14109193)
100. F. Gobeil, M. Montagne, N. Inamura, and D. Regoli Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657) Immunopharmacology 43 1999 179 185
101. F. Gobeil, S. Halle, P.A. Blais, and D. Regoli Studies on the angiotensin-converting enzyme and the kinin B2 receptor in the rabbit jugular vein: modulation of contractile response to bradykinin Can J Physiol Pharmacol 80 2002 153 163
102. F. Gobeil, L.H. Pheng, I. Badini, X.K. Nguyen-Le, A. Pizard, and A. Rizzi Receptors for kinins in the human isolated umbilical vein Br J Pharmacol 118 1996 289 294 (Pubitemid 26149274)
103. E.M. Golding, S.P. Marrelli, J. You, and R.M. Bryan Jr. Endothelium-derived hyperpolarizing factor in the brain: a new regulator of cerebral blood flow? Stroke 33 2002 661 663 (Pubitemid 34203985)
104. A.M. Grandi Antihypertensive therapy: role of aldosterone antagonists Curr Pharm Des 11 2005 2235 2242 (Pubitemid 40872713)
105. V. Griol-Charhbili, E. Messadi-Laribi, J.L. Bascands, D. Heudes, P. Meneton, and J.F. Giudicelli Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia FASEB J 19 2005 1172 1174 (Pubitemid 40946455)
106. J.L. Grobe, A.P. Mecca, M. Lingis, V. Shenoy, T.A. Bolton, and J.M. Machado Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7) Am J Physiol Heart Circ Physiol 292 2007 H736 742
107. R.J. Gryglewski Prostacyclin among prostanoids Pharmacol Rep 60 2008 3 11 (Pubitemid 351586537)
108. R.J. Gryglewski, and S. Moncada Secretory function of vascular endothelium Adv Prostaglandin Thromboxane Leukot Res 17A 1987 397 404
109. D.G. Hackam, N.A. Khan, B.R. Hemmelgarn, S.W. Rabkin, R.M. Touyz, and N.R. Campbell The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy Can J Cardiol 26 2010 249 258
110. J.M. Hall Bradykinin receptors: pharmacological properties and biological roles Pharmacol Ther 56 1992 131 190 (Pubitemid 23085319)
111. J.M. Hall Bradykinin receptors Gen Pharmacol 28 1997 1 6 (Pubitemid 27016051)
112. J.L. Hansen, J.T. Hansen, T. Speerschneider, C. Lyngso, N. Erikstrup, and E.S. Burstein Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: how common is the AT1R/B2R heterodimer? J Biol Chem 284 2009 1831 1839
113. L. Hansson, L.H. Lindholm, T. Ekbom, B. Dahlof, J. Lanke, and B. Schersten Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study Lancet 354 1999 1751 1756
114. L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, and A. Niklason Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616 (Pubitemid 29087980)
115. N. Hayashi, K. Yamamoto, M. Ohishi, Y. Tatara, Y. Takeya, and A. Shiota The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells Hypertens Res 33 2010 1182 1185
116. H. Heitsch The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease Expert Opin Investig Drugs 12 2003 759 770 (Pubitemid 36622185)
117. J.F. Hess, J.A. Borkowski, G.S. Young, C.D. Strader, and R.W. Ransom Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor Biochem Biophys Res Commun 184 1992 260 268
118. P. Hillmeister, N. Gatzke, A. Dulsner, M. Bader, I. Schadock, and I. Hoefer Arteriogenesis is modulated by bradykinin receptor signaling Circ Res 109 2011 524 533
119. B. Hornig, C. Kohler, and H. Drexler Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans Circulation 95 1997 1115 1118 (Pubitemid 27097818)
120. B. Hornig, C. Kohler, D. Schlink, H. Tatge, and H. Drexler AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism Hypertension 41 2003 1092 1095 (Pubitemid 36548608)
121. T. Ignjatovic, F. Tan, V. Brovkovych, R.A. Skidgel, and E.G. Erdos Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor J Biol Chem 277 2002 16847 16852 (Pubitemid 34967708)
122. T. Ignjatovic, S. Stanisavljevic, V. Brovkovych, R.A. Skidgel, and E.G. Erdos Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands Mol Pharmacol 66 2004 1310 1316 (Pubitemid 39411071)
123. C. Imai, A. Okamura, J.F. Peng, Y. Kitamura, and M.P. Printz Interleukin-1beta enhanced action of kinins on extracellular matrix of spontaneous hypertensive rat cardiac fibroblasts Clin Exp Hypertens 27 2005 59 69 (Pubitemid 40315208)
124. IMS-Health Top Therapeutic Classes by U.S. Dispensed Prescriptions 2010 http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/Top%20Therapy%20Classes%20by%20U.S.RXs.pdf
125. K. Inokuchi, Y. Hirooka, H. Shimokawa, K. Sakai, T. Kishi, and K. Ito Role of endothelium-derived hyperpolarizing factor in human forearm circulation Hypertension 42 2003 919 924 (Pubitemid 37413731)
126. M. Iwai, and M. Horiuchi Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis Hypertens Res 32 2009 533 536
127. M. Iwata, R.T. Cowling, D. Gurantz, C. Moore, S. Zhang, and J.X. Yuan Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects Am J Physiol Heart Circ Physiol 289 2005 H2356 2363
128. E.K. Jackson Renin and Angiotensin L.S. Goodman, A. Gilman, L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman & Gilman's the pharmacological basis of therapeutics 11th ed 2006 McGraw-Hill New York 789 pp
129. A. Jalowy, R. Schulz, H. Dorge, M. Behrends, and G. Heusch Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs J Am Coll Cardiol 32 1998 1787 1796 (Pubitemid 28545220)
130. A.S. Janoff Private development companies: transforming academic research into new treatment options for cancer Mol Interv 10 2010 65 68
131. H. Jing, J. Qin, M. Feng, T. Wang, J. Zhu, and C. Wang Nitric oxide in enteric nervous system mediated the inhibitory effect of vasopressin on the contraction of circular muscle strips from colon in male rats Neurogastroenterol Motil 23 2011 e125 135
132. JNC7 The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure 2004 NIH publication 86
133. E.S. Jones, A. Vinh, C.A. McCarthy, T.A. Gaspari, and R.E. Widdop AT2 receptors: functional relevance in cardiovascular disease Pharmacol Ther 120 2008 292 316
134. H. Ju, V.J. Venema, M.B. Marrero, and R.C. Venema Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase J Biol Chem 273 1998 24025 24029 (Pubitemid 28435743)
135. M. Kakoki, and O. Smithies The kallikrein-kinin system in health and in diseases of the kidney Kidney Int 75 2009 1019 1030
136. M. Kakoki, N. Takahashi, J.C. Jennette, and O. Smithies Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor Proc Natl Acad Sci U S A 101 2004 13302 13305 (Pubitemid 39209660)
137. M. Kakoki, R.W. McGarrah, H.S. Kim, and O. Smithies Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury Proc Natl Acad Sci U S A 104 2007 7576 7581 (Pubitemid 47185948)
138. M. Kakoki, C.M. Kizer, X. Yi, N. Takahashi, H.S. Kim, and C.R. Bagnell Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors J Clin Invest 116 2006 1302 1309
139. M. Kakoki, K.A. Sullivan, C. Backus, J.M. Hayes, S.S. Oh, and K. Hua Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice Proc Natl Acad Sci U S A 107 2010 10190 10195
140. B.L. Kasiske, R.S. Kalil, J.Z. Ma, M. Liao, and W.F. Keane Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis Ann Intern Med 118 1993 129 138
141. N. Kloth, and A.S. Lane ACE inhibitor-induced angioedema: a case report and review of current management Crit Care Resusc 13 2011 33 37
142. F. Kuhr, J. Lowry, Y. Zhang, V. Brovkovych, and R.A. Skidgel Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors Neuropeptides 44 2010 145 154
143. S. Kurisu, R. Ozono, T. Oshima, M. Kambe, T. Ishida, and H. Sugino Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis Hypertension 41 2003 99 107 (Pubitemid 36056799)
144. J. Labonte, I. Brochu, J.C. Honore, and P. D'Orleans-Juste Role of ETB and B2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse Br J Pharmacol 132 2001 934 940 (Pubitemid 32193651)
145. C. Lagneux, A. Adam, and D. Lamontagne A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart Int Immunopharmacol 3 2003 1511 1518 (Pubitemid 37025732)
146. M. Lamarre-Cliche, and P. Larochelle Evaluative and epidemiological approaches of ACE therapy P. D'Orléans-Juste, G.E. Plante, ACE inhibitors 2001 Birkhäuser Basel 47 70
147. H. Langberg, C. Bjorn, R. Boushel, Y. Hellsten, and M. Kjaer Exercise-induced increase in interstitial bradykinin and adenosine concentrations in skeletal muscle and peritendinous tissue in humans J Physiol 542 2002 977 983 (Pubitemid 34947288)
148. L.M. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D.J. Pettibone, and B.L. Zuraw International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences Pharmacol Rev 57 2005 27 77 (Pubitemid 40283969)
149. M.A. Leesar, M.F. Stoddard, S. Manchikalapudi, and R. Bolli Bradykinin-induced preconditioning in patients undergoing coronary angioplasty J Am Coll Cardiol 34 1999 639 650 (Pubitemid 29436166)
150. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, and J.B. Lewis Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
151. I. Liesmaa, J.O. Kokkonen, P.T. Kovanen, and K.A. Lindstedt Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells J Mol Cell Cardiol 43 2007 593 600 (Pubitemid 47615049)
152. W. Linz, G. Wiemer, P. Gohlke, T. Unger, and B.A. Scholkens Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors Pharmacol Rev 47 1995 25 49
153. W. Linz, P. Wohlfart, B.A. Scholkens, T. Malinski, and G. Wiemer Interactions among ACE, kinins and NO Cardiovasc Res 43 1999 549 561 (Pubitemid 29369254)
154. B. Liu, J. Yu, L. Taylor, X. Zhou, and P. Polgar Microarray and phosphokinase screenings leading to studies on ERK and JNK regulation of connective tissue growth factor expression by angiotensin II 1a and bradykinin
155. Y.H. Liu, X.P. Yang, V.G. Sharov, D.H. Sigmon, H.N. Sabbath, and O.A. Carretero Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats Hypertension 27 1996 7 13 (Pubitemid 26017674)
156. Y.H. Liu, X.P. Yang, V.G. Sharov, O. Nass, H.N. Sabbah, and E. Peterson Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors J Clin Invest 99 1997 1926 1935 (Pubitemid 27175940)
157. R.A. Loiola, F.C. Reis, E.M. Kawamoto, C. Scavone, D.S. Abdalla, and L. Fernandes Role of vascular Kinin B(1) and B(2) receptors in endothelial nitric oxide metabolism Peptides 32 2011 1700 1705
158. A.E. Loot, A.J. Roks, R.H. Henning, R.A. Tio, A.J. Suurmeijer, and F. Boomsma Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats Circulation 105 2002 1548 1550 (Pubitemid 34297630)
159. M. Lortie, D. Regoli, N.E. Rhaleb, and G.E. Plante The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin Am J Physiol 262 1992 R72 76
160. C. Lyngso, N. Erikstrup, and J.L. Hansen Functional interactions between 7TM receptors in the renin-angiotensin system-dimerization or crosstalk? Mol Cell Endocrinol 302 2009 203 212
161. P. Madeddu Stem cell therapy for cardiovascular regeneration: The beginning or the end of all hearts' hopes Pharmacol Ther 2010
162. P. Madeddu, C. Emanueli, and S. El-Dahr Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling Nat Clin Pract Nephrol 3 2007 208 221 (Pubitemid 46496868)
163. C.A. Maggi Bradykinin as an Inflammatory Mediator in the Urinary Tract S.G. Farmer, The Kinin system 1997 Academic Press San Diego 235 247
164. G. Mancia, C. Giannattasio, G. Grassi, A. Morganti, and A. Zanchetti Reflex control of circulation and angiotensin converting enzyme inhibition in man J Hypertens Suppl 6 1988 S45 49
165. G. Mancia, G. Parati, M. Revera, G. Bilo, A. Giuliano, and F. Veglia Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial BMJ 340 2010 c1197
166. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, and M.J. Caulfield Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2009 2121 2158
167. G.B. Mancini, G.C. Henry, C. Macaya, B.J. O'Neill, A.L. Pucillo, and R.G. Carere Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study Circulation 94 1996 258 265 (Pubitemid 26266107)
168. T.A. Manolio, J.A. Cutler, C.D. Furberg, B.M. Psaty, P.K. Whelton, and W.B. Applegate Trends in pharmacologic management of hypertension in the United States Arch Intern Med 155 1995 829 837
169. A.J. Manolis, M.E. Marketou, I. Gavras, and H. Gavras Cardioprotective properties of bradykinin: role of the B(2) receptor Hypertens Res 33 2010 772 777
170. F. Marceau Kinin B1 receptors: a review Immunopharmacology 30 1995 1 26
171. F. Marceau, and D. Regoli Bradykinin receptor ligands: therapeutic perspectives Nat Rev Drug Discov 3 2004 845 852 (Pubitemid 39405945)
172. F. Marceau, and D. Regoli Therapeutic options in inflammatory bowel disease: experimental evidence of a beneficial effect of kinin B1 receptor blockade Br J Pharmacol 154 2008 1163 1165 (Pubitemid 351992072)
173. F. Marceau, J.F. Hess, and D.R. Bachvarov The B1 receptors for kinins Pharmacol Rev 50 1998 357 386
174. M. Marin-Grez, P. Cottone, and O.A. Carretero Evidence for an involvement of kinins in regulation of sodium excretion Am J Physiol 223 1972 794 796
175. M. Marketou, E. Kintsurashvili, K.N. Papanicolaou, H.A. Lucero, I. Gavras, and H. Gavras Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct Am J Hypertens 23 2010 562 568
176. F.D. Marques, A.J. Ferreira, R.D. Sinisterra, B.A. Jacoby, F.B. Sousa, and M.V. Caliari An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats Hypertension 57 2011 477 483
177. M. Marre, G. Chatellier, H. Leblanc, T.T. Guyene, J. Menard, and P. Passa Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria BMJ 297 1988 1092 1095
178. T. Matsumoto, H. Horie, K. Minai, H. Yokohama, H. Takashima, and N. Ohira Coronary vasomotor responses to bradykinin and acetylcholine in patients with coronary spastic angina Jpn Circ J 65 2001 1052 1056
179. S.I. McFarlane, M. Banerji, and J.R. Sowers Insulin resistance and cardiovascular disease J Clin Endocrinol Metab 86 2001 713 718 (Pubitemid 32207485)
180. S.I. McFarlane, A. Kumar, and J.R. Sowers Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease Am J Cardiol 91 2003 30H 37H (Pubitemid 36724893)
181. P.G. McLean, M. Perretti, and A. Ahluwalia Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin- induced coronary vasodilation Br J Pharmacol 128 1999 275 282 (Pubitemid 29458585)
182. D. Mehta, and A.B. Malik Signaling mechanisms regulating endothelial permeability Physiol Rev 86 2006 279 367
183. J.G. Menke, J.A. Borkowski, K.K. Bierilo, T. MacNeil, A.W. Derrick, and K.A. Schneck Expression cloning of a human B1 bradykinin receptor J Biol Chem 269 1994 21583 21586 (Pubitemid 24274792)
184. V.F. Merino, M. Todiras, L.A. Campos, V. Saul, E. Popova, and O.C. Baltatu Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors J Mol Med (Berl) 86 2008 791 798
185. E. Messadi-Laribi, V. Griol-Charhbili, E. Gaies, M.P. Vincent, D. Heudes, and P. Meneton Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice Clin Exp Pharmacol Physiol 35 2008 489 493 (Pubitemid 351326785)
186. K. Minai, T. Matsumoto, H. Horie, N. Ohira, H. Takashima, and H. Yokohama Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors J Am Coll Cardiol 37 2001 1565 1570
187. J.V. Mombouli, and P.M. Vanhoutte Endothelial dysfunction: from physiology to therapy J Mol Cell Cardiol 31 1999 61 74 (Pubitemid 29078219)
188. N. Momose, K. Fukuo, S. Morimoto, and T. Ogihara Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin Hypertension 21 1993 921 924 (Pubitemid 23166940)
189. A.C. Monteiro, V. Schmitz, E. Svensjo, R.T. Gazzinelli, I.C. Almeida, and A. Todorov Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi J Immunol 177 2006 6325 6335 (Pubitemid 44628851)
190. G. Morissette, J.P. Couture, A. Desormeaux, A. Adam, and F. Marceau Lack of direct interaction between enalaprilat and the kinin B1 receptors Peptides 29 2008 606 612
191. M. Mousli, J.L. Bueb, C. Bronner, B. Rouot, and Y. Landry G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides Trends Pharmacol Sci 11 1990 358 362 (Pubitemid 20262461)
192. L.J. Murphey, H.A. Malave, J. Petro, I. Biaggioni, D.W. Byrne, and D.E. Vaughan Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans J Pharmacol Exp Ther 318 2006 1287 1292 (Pubitemid 44268337)
193. T. Nagao, and P.M. Vanhoutte Endothelium-derived hyperpolarizing factor and endothelium-dependent relaxations Am J Respir Cell Mol Biol 8 1993 1 6
194. M. Nakashima, J.V. Mombouli, A.A. Taylor, and P.M. Vanhoutte Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries J Clin Invest 92 1993 2867 2871 (Pubitemid 24006555)
195. K.K. Ng, and J.R. Vane Conversion of angiotensin I to angiotensin II Nature 216 1967 762 766
196. S. Nsa Allogho, F. Gobeil, S.I. Perron, J.F. Hess, and D. Regoli Effects of kinins on isolated stomachs of control and transgenic knockout B2 receptor mice Naunyn Schmiedebergs Arch Pharmacol 357 1998 191 196 (Pubitemid 28112566)
197. M.A. Ondetti, and D.W. Cushman Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions CRC Crit Rev Biochem 16 1984 381 411
198. M.A. Ondetti, N.J. Williams, E.F. Sabo, J. Pluscec, E.R. Weaver, and O. Kocy Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis Biochemistry 10 1971 4033 4039
199. J.R. Parratt Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation Trends Pharmacol Sci 15 1994 19 25 (Pubitemid 24027446)
200. J.R. Parratt, A. Vegh, and J.G. Papp Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning-A brief review of the evidence Can J Physiol Pharmacol 73 1995 837 842
201. J.B. Pesquero, and M. Bader Genetically altered animal models in the kallikrein-kinin system Biol Chem 387 2006 119 126 (Pubitemid 43221824)
202. M.A. Pfeffer Left ventricular remodeling after acute myocardial infarction Annu Rev Med 46 1995 455 466
203. M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, and E.L. Michelson Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766 (Pubitemid 37093915)
204. S.V. Pinheiro, A.C. Simoes e Silva, W.O. Sampaio, R.D. de Paula, E.P. Mendes, and E.D. Bontempo Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney Hypertension 44 2004 490 496 (Pubitemid 39281501)
205. A. Pinto, N.G. Abraham, and K.M. Mullane Cytochrome P-450-dependent monooxygenase activity and endothelial-dependent relaxations induced by arachidonic acid J Pharmacol Exp Ther 236 1986 445 451 (Pubitemid 16184240)
206. A. Prasad, S. Husain, and A.A. Quyyumi Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin J Am Coll Cardiol 33 1999 796 804
207. M. Pretorius, D. Rosenbaum, D.E. Vaughan, and N.J. Brown Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin Circulation 107 2003 579 585 (Pubitemid 36176808)
208. B.M. Psaty, T.A. Manolio, N.L. Smith, S.R. Heckbert, J.S. Gottdiener, and G.L. Burke Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study Arch Intern Med 162 2002 2325 2332 (Pubitemid 35332515)
209. T. Quaschning Vasopeptidase inhibition for blood pressure control: emerging experience Curr Pharm Des 11 2005 3293 3299 (Pubitemid 41300778)
210. T. Quaschning, B. Hocher, S. Ruhl, A. Kraemer-Guth, J. Tilgner, and C. Wanner Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension Kidney Blood Press Res 29 2006 351 359 (Pubitemid 46143902)
211. D.M. Rabi, S.S. Daskalopoulou, R.S. Padwal, N.A. Khan, S.A. Grover, and D.G. Hackam The 2011 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy Can J Cardiol 27 415-433 2011 e412
212. M. Rapacon, P. Mieyal, J.C. McGiff, D. Fulton, and J. Quilley Contribution of calcium-activated potassium channels to the vasodilator effect of bradykinin in the isolated, perfused kidney of the rat Br J Pharmacol 118 1996 1504 1508 (Pubitemid 26248805)
213. M. Ravid, H. Savin, I. Jutrin, T. Bental, B. Katz, and M. Lishner Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients Ann Intern Med 118 1993 577 581 (Pubitemid 23102690)
214. M. Ravid, D. Brosh, Z. Levi, Y. Bar-Dayan, D. Ravid, and R. Rachmani Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial Ann Intern Med 128 1998 982 988 (Pubitemid 28275174)
215. D. Regoli Pharmacology of nitric oxide: molecular mechanisms and therapeutic strategies Curr Pharm Des 10 2004 1667 1676
216. D. Regoli, and J. Barabé Pharmacology of bradykinin and related kinins Pharmacol Rev 32 1980 1 46
217. D. Regoli, and F. Gobeil Peptide receptors. From classical pharmacology to molecular biology: The case of kinin receptors P. Geppetti, W. Müller-Esterl, D. Regoli, Peptidergic G protein-coupled receptors: from basic research to clinical applications vol. 307 1999 IOS Press Amsterdam; Washington, DC 64 77
218. D. Regoli, W.K. Park, and F. Rioux Pharmacology of angiotensin Pharmacol Rev 26 1974 69 123
219. D. Regoli, F. Marceau, and J. Lavigne Induction of B1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide Eur J Pharmacol 71 1981 105 115 (Pubitemid 11112570)
220. D. Regoli, N.E. Rhaleb, S. Dion, and G. Drapeau New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization Trends Pharmacol Sci 11 1990 156 161 (Pubitemid 20118009)
221. D. Regoli, S. Nsa Allogho, A. Rizzi, and F.J. Gobeil Bradykinin receptors and their antagonists Eur J Pharmacol 348 1998 1 10 (Pubitemid 28266747)
222. K. Rett, M. Wicklmayr, and G. Dietze New aspects of local vasodilatory and metabolic effects of the kallikrein-kinin system. its role during muscle work H. Fritz, I. Schmidt, G. Dietze, Conference 1989 Limbach-Verlag Braunschweig 97 108 NameConference, Location
223. N.E. Rhaleb, X.P. Yang, and O.A. Carretero The Kallikrein-Kinin System as a Regulator of Cardiovascular and Renal Function Compr Physiol 2011 971 993
224. G. Riccioni, N. Vitulano, A. Zanasi, F. Bellocci, and N. d'Orazio Aliskiren: beyond blood pressure reduction Expert Opin Investig Drugs 19 2010 1265 1274
225. D. Rodi, R. Couture, B. Ongali, and M. Simonato Targeting kinin receptors for the treatment of neurological diseases Curr Pharm Des 11 2005 1313 1326 (Pubitemid 40458276)
226. F. Roskiewicz, I. Andriamanana, V. Gras-Champel, M. Andrejak, and Z.A. Massy Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers Nephrol Ther 3 2007 89 95 (Pubitemid 46830689)
227. N. Rouissi, F. Nantel, G. Drapeau, N.E. Rhaleb, S. Dion, and D. Regoli Inhibitors of peptidases: how they influence the biological activities of substance P, neurokinins, bradykinin and angiotensin in guinea pig, hamster and rat urinary bladders Pharmacology 40 1990 196 204 (Pubitemid 20214289)
228. N. Rouissi, F. Nantel, G. Drapeau, N.E. Rhaleb, S. Dion, and D. Regoli Inhibitors of peptidases: how they influence the biological activities of substance P, neurokinins, kinins and angiotensins in isolated vessels Pharmacology 40 1990 185 195 (Pubitemid 20214288)
229. C.H. Ruan, S.P. So, and K.H. Ruan Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease Life Sci 88 2011 24 30
230. D.R. Santos, J.B. Calixto, and G.E. Souza Effect of a kinin B2 receptor antagonist on LPS- and cytokine-induced neutrophil migration in rats Br J Pharmacol 139 2003 271 278 (Pubitemid 36760359)
231. R.A. Santos, A.J. Ferreira, S.V. Pinheiro, W.O. Sampaio, R. Touyz, and M.J. Campagnole-Santos Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs Expert Opin Investig Drugs 14 2005 1019 1031 (Pubitemid 41131653)
232. T. Sasaoka, Y. Egi, M. Tawa, A. Yamamoto, M. Ohkita, and M. Takaoka Angiotensin II type 2 receptor-mediated inhibition of norepinephrine release in isolated rat hearts J Cardiovasc Pharmacol 52 2008 176 183
233. M. Sato, R.M. Engelman, H. Otani, N. Maulik, J.A. Rousou, and J.E. Flack III Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms Circulation 102 2000 III346 351
234. J.P. Schanstra, E. Neau, P. Drogoz, M.A. Arevalo Gomez, J.M. Lopez Novoa, and D. Calise In vivo bradykinin B2 receptor activation reduces renal fibrosis J Clin Invest 110 2002 371 379 (Pubitemid 34847969)
235. J. Scharfstein, V. Schmitz, V. Morandi, M.M. Capella, A.P. Lima, and A. Morrot Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors J Exp Med 192 2000 1289 1300
236. U. Schulze-Topphoff, A. Prat, T. Prozorovski, V. Siffrin, M. Paterka, and J. Herz Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system Nat Med 15 2009 788 793
237. N. Seyedi, T. Win, H.M. Lander, and R. Levi Bradykinin B2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings. Mediation by autocrine/paracrine mechanisms Circ Res 81 1997 774 784 (Pubitemid 27467212)
238. Z. Shariat-Madar, F. Mahdi, and A.H. Schmaier Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator J Biol Chem 277 2002 17962 17969 (Pubitemid 34967607)
239. Z. Shariat-Madar, E. Rahimy, F. Mahdi, and A.H. Schmaier Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells Am J Physiol Heart Circ Physiol 289 2005 H2697 2703
240. J.N. Sharma Cardiovascular activities of the bradykinin system ScientificWorldJournal 8 2008 384 393 (Pubitemid 351669776)
241. J.N. Sharma, and R.B. Thani Therapeutic prospects for bradykinin receptor agonists in the treatment of cardiovascular diseases IDrugs 7 2004 926 934 (Pubitemid 39429852)
242. M. Shino, K. Takahashi, T. Murata, H. Iida, Y. Yasuoka, and N. Furuya Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis Am J Otolaryngol 32 2011 624 626
243. I. Sipahi, S.M. Debanne, D.Y. Rowland, D.I. Simon, and J.C. Fang Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol 11 2010 627 636
244. L.T. Skeggs Jr., J.R. Kahn, and N.P. Shumway The preparation and function of the hypertensin-converting enzyme J Exp Med 103 1956 295 299
245. D. Smith, M. Gilbert, and W.G. Owen Tissue plasminogen activator release in vivo in response to vasoactive agents Blood 66 1985 835 839 (Pubitemid 15242467)
246. J.R. Sowers, M. Epstein, and E.D. Frohlich Diabetes, hypertension, and cardiovascular disease: an update Hypertension 37 2001 1053 1059 (Pubitemid 32304003)
247. A. Stadnicki Intestinal tissue kallikrein-kinin system in inflammatory bowel disease Inflamm Bowel Dis 17 2011 645 654
248. S. Stanisavljevic, T. Ignjatovic, P.A. Deddish, V. Brovkovych, K. Zhang, and E.G. Erdos Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells J Pharmacol Exp Ther 316 2006 1153 1158 (Pubitemid 43345289)
249. U.M. Steckelings, F. Rompe, E. Kaschina, P. Namsolleck, A. Grzesiak, and H. Funke-Kaiser The past, present and future of angiotensin II type 2 receptor stimulation J Renin Angiotensin Aldosterone Syst 11 2010 67 73
250. J.B. Su Kinins and cardiovascular diseases Curr Pharm Des 12 2006 3423 3435 (Pubitemid 44364129)
251. J.B. Su, R. Houel, F. Heloire, F. Barbe, F. Beverelli, and L. Sambin Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation Circulation 101 2000 1848 1853 (Pubitemid 30213108)
252. E.A. Tallant, C.M. Ferrario, and P.E. Gallagher Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor Am J Physiol Heart Circ Physiol 289 2005 H1560 1566
253. L. Taraseviciene-Stewart, R. Scerbavicius, J.M. Stewart, L. Gera, Y. Demura, and C. Cool Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy Peptides 26 2005 1292 1300 (Pubitemid 41021462)
254. The-ACE-Inhibitors-in-Diabetic-Nephropathy-Trialist-Group Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data Ann Intern Med 134 2001 370 379
255. The-GISEN-Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Lancet 349 1997 1857 1863
256. C.P. Tiefenbacher, S. Friedrich, T. Bleeke, C. Vahl, X. Chen, and F. Niroomand ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles Am J Physiol Heart Circ Physiol 286 2004 H1425 1432
257. P.B. Timmermans, P.C. Wong, A.T. Chiu, W.F. Herblin, P. Benfield, and D.J. Carini Angiotensin II receptors and angiotensin II receptor antagonists Pharmacol Rev 45 1993 205 251 (Pubitemid 23191415)
258. B. Tom, A. Dendorfer, R. de Vries, P.R. Saxena, and A.H. Jan Danser Bradykinin potentiation by ACE inhibitors: a matter of metabolism Br J Pharmacol 137 2002 276 284
259. D. Tonduangu, L. Hittinger, B. Ghaleh, P. Le Corvoisier, L. Sambin, and S. Champagne Chronic infusion of bradykinin delays the progression of heart failure and preserves vascular endothelium-mediated vasodilation in conscious dogs Circulation 109 2004 114 119 (Pubitemid 38056031)
260. C. Tschope, F. Spillmann, C. Altmann, M. Koch, D. Westermann, and N. Dhayat The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction Cardiovasc Res 61 2004 559 569 (Pubitemid 38210161)
261. Y. Tsutsumi, H. Matsubara, H. Masaki, H. Kurihara, S. Murasawa, and S. Takai Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation J Clin Invest 104 1999 925 935 (Pubitemid 29536342)
262. T. Unger, and B. Dahlof Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential J Renin Angiotensin Aldosterone Syst 11 2010 75 77
263. J.R. Vane The release and fate of vaso-active hormones in the circulation Br J Pharmacol 35 1969 209 242
264. J.R. Vane The Croonian Lecture, 1993: The Endothelium: Maestro of the Blood Circulation Philos Trans R Soc Lond B Biol Sci 343 1994 225 246 (Pubitemid 2042011)
265. P.M. Vanhoutte Endothelial dysfunction: the first step toward coronary arteriosclerosis Circ J 73 2009 595 601
266. P.M. Vanhoutte, C.M. Boulanger, and J.V. Mombouli Endothelium-derived relaxing factors and converting enzyme inhibition Am J Cardiol 76 1995 3E 12E
267. R.J. Vavrek, L. Gera, and J.M. Stewart Pseudopeptide analogs of bradykinin and bradykinin antagonists Agents Actions Suppl 38 Pt 1 1992 565 571
268. B. Waeber, I. Gavras, H.R. Brunner, C.A. Cook, F. Charocopos, and H.P. Gavras Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity Am Heart J 103 1982 384 390 (Pubitemid 12178722)
269. P.E. Walters, T.A. Gaspari, and R.E. Widdop Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats Hypertension 45 2005 960 966 (Pubitemid 40628944)
270. X. Wang, M. Wei, P. Kuukasjarvi, J. Laurikka, T. Rinne, and E. Moilanen The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning) Scand Cardiovasc J 43 2009 72 79
271. M. Wei, X. Wang, P. Kuukasjarvi, J. Laurikka, T. Rinne, and E.L. Honkonen Bradykinin preconditioning in coronary artery bypass grafting Ann Thorac Surg 78 2004 492 497 (Pubitemid 38980760)
272. J. Wharton, K. Morgan, R.A. Rutherford, J.D. Catravas, A. Chester, and B.F. Whitehead Differential distribution of angiotensin AT2 receptors in the normal and failing human heart J Pharmacol Exp Ther 284 1998 323 336 (Pubitemid 28109563)
273. G. Wiemer, L.W. Dobrucki, F.R. Louka, T. Malinski, and H. Heitsch AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium Hypertension 40 2002 847 852 (Pubitemid 35434905)
274. G.H. Williams Converting-enzyme inhibitors in the treatment of hypertension N Engl J Med 319 1988 1517 1525 (Pubitemid 19003411)
275. K.C. Wollert, and H. Drexler The renin-angiotensin system and experimental heart failure Cardiovasc Res 43 1999 838 849 (Pubitemid 29413183)
276. L. Xi, A. Das, Z.Q. Zhao, V.F. Merino, M. Bader, and R.C. Kukreja Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice Circulation 118 2008 S32 37
277. J. Xu, O.A. Carretero, Y.H. Liu, E.G. Shesely, F. Yang, and A. Kapke Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice Hypertension 40 2002 244 250 (Pubitemid 35006705)
278. J. Xu, O.A. Carretero, E.G. Shesely, N.E. Rhaleb, J.J. Yang, and M. Bader The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice Exp Physiol 94 2009 322 329
279. A. Yamamoto, L.C. Keil, and I.A. Reid Effect of intrarenal bradykinin infusion on vasopressin release in rabbits Hypertension 19 1992 799 803
280. Y.Y. Yao, H. Yin, B. Shen, L. Chao, and J. Chao Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction J Card Fail 13 2007 588 596 (Pubitemid 47362752)
281. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
282. R. Zatz, B.R. Dunn, T.W. Meyer, S. Anderson, H.G. Rennke, and B.M. Brenner Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension J Clin Invest 77 1986 1925 1930 (Pubitemid 16062649)
283. X. Zhang, F. Tan, Y. Zhang, and R.A. Skidgel Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists J Biol Chem 283 2008 7994 8004
284. X. Zhang, F. Tan, V. Brovkovych, Y. Zhang, and R.A. Skidgel Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling J Biol Chem 286 2011 18547 18561
285. X.S. Zhang, J.H. Ren, J.P. Lu, and Y. Fan Atorvastatin protects against angiotensin II-induced injury and dysfunction in human umbilical vein endothelial cells through bradykinin 2 receptors J Cardiovasc Pharmacol 56 2010 171 176
286. Y. Zhao, Q. Qiu, F. Mahdi, Z. Shariat-Madar, R. Rojkjaer, and A.H. Schmaier Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation Am J Physiol Heart Circ Physiol 280 2001 H1821 1829
287. L. Zhu, O.A. Carretero, T.D. Liao, P. Harding, H. Li, and C. Sumners Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells Hypertension 56 2010 384 390
288. P. Zhu, C.E. Zaugg, P.S. Hornstein, P.R. Allegrini, and P.T. Buser Bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts J Cardiovasc Pharmacol 33 1999 785 790 (Pubitemid 29196718)